Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
NCT03003728 · University of Arkansas · PHASE2 · withdrawn · last registry update 2020-07-10 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawal of study support” | Open Targets' class: business administrative | Registry record, University of Arkansas |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLAMF7 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-07-01Results posted on the registry: Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01891643)
- 2021-07-01Also stopped (terminated): Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01891643)
- 2020-10-22Results posted on the registry: Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01335399)
- 2020-08-06Results posted on the registry: Bristol-Myers Squibb, Elotuzumab + Pomalidomide (NCT02612779)
- 2019-07-17Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Elotuzumab (NCT03393273)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision